EwerM.S., VooletichM.T., DurandJ.B., WoodsM.L., DavisJ.R., ValeroV., LenihanD.J.: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol, 23: 7820–7826, 2005.
2.
JensenB.V.: Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol, 33: S15–21, 2006.
3.
McArthurH.L., ChiaS.: Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med, 357: 94–95, 2007.
4.
SpeyerJ.: Cardiac dysfunction in the trastuzumab clinical experience. J Clin Oncol, 20: 1156–1157, 2002.
5.
EwerM.S., GibbsH.R., SwaffordJ., BenjaminR.S.: Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artefact?Semin Oncol,26: 96–101, 1999.
6.
HuntS.A., AbrahamW.T., ChinM.H., FeldmanA.M., FrancisG.S., GaniatsT.G., JessupM., KonstamM.A., ManciniD.M., MichlK., OatesJ.A., RahkoP.S., SilverM.A., StevensonL.W., YancyC.W., AntmanE.M., SmithS.C.Jr., AdamsC.D., AndersonJ.L., FaxonD.P., FusterV., HalperinJ.L., HiratzkaL.F., JacobsA.K., NishimuraR., OrnatoJ.P., PageR.L., RiegelB.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation,112(12): e154–235, 2005.
7.
CardinaleD., SandriM.T., ColomboA., ColomboN., BoeriM., LamantiaG., CivelliM., PeccatoriF., MartinelliG., FiorentiniC., CipollaC.M.: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation, 109: 2749–2754, 2004.
8.
ChiaS., ClemonsM., MartinL.A., RodgersA., GelmonK., PondG.R., PanasciL.: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial. J Clin Oncol, 24: 2773–2778, 2006.